134 related articles for article (PubMed ID: 10471096)
1. The effects of the peptide-coupling agent, EEDQ, on 5-HT2A receptor binding and function in rat frontal cortex.
Kettle CJ; Cheetham SC; Martin KF; Prow MR; Heal DJ
Neuropharmacology; 1999 Sep; 38(9):1421-30. PubMed ID: 10471096
[TBL] [Abstract][Full Text] [Related]
2. Regulation of 5-HT(2A) receptor mRNA levels and binding sites in rat frontal cortex by the agonist DOI and the antagonist mianserin.
Anji A; Kumari M; Sullivan Hanley NR; Bryan GL; Hensler JG
Neuropharmacology; 2000 Aug; 39(11):1996-2005. PubMed ID: 10963743
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characteristics and regulation of 5-HT receptor-stimulated phosphoinositide hydrolysis in the rat spinal cord.
Toscano E; Romero G; Oset C; Del Río J
Gen Pharmacol; 1999 Mar; 32(3):351-8. PubMed ID: 10211591
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain.
Gozlan H; Laporte AM; Thibault S; Schechter LE; Bolaños F; Hamon M
Neuropharmacology; 1994; 33(3-4):423-31. PubMed ID: 7984280
[TBL] [Abstract][Full Text] [Related]
5. Regional heterogeneity of serotonin(1A) receptor inactivation and turnover in the aging female rat brain following EEDQ.
Keck BJ; Lakoski JM
Neuropharmacology; 2000 Apr; 39(7):1237-46. PubMed ID: 10760365
[TBL] [Abstract][Full Text] [Related]
6. Facilitation by 8-OH-DPAT of passive avoidance performance in rats after inactivation of 5-HT(1A) receptors.
Otano A; García-Osta A; Ballaz S; Frechilla D; Del Río J
Br J Pharmacol; 1999 Dec; 128(8):1691-8. PubMed ID: 10588924
[TBL] [Abstract][Full Text] [Related]
7. In vivo estimates of efficacy at 5-HT1A receptors: effects of EEDQ on the ability of agonists to produce lower-lip retraction in rats.
Koek W; Assié MB; Zernig G; France CP
Psychopharmacology (Berl); 2000 May; 149(4):377-87. PubMed ID: 10867965
[TBL] [Abstract][Full Text] [Related]
8. N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) administration for studies of 5-HT1A receptor binding site inactivation and turnover.
Keck BJ; Lakoski JM
Brain Res Brain Res Protoc; 1997 Oct; 1(4):364-70. PubMed ID: 9384817
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of 5-HT(1A) receptors in hippocampal and cortical homogenates.
Alper RH; Nelson DL
Eur J Pharmacol; 2000 Feb; 390(1-2):67-73. PubMed ID: 10708708
[TBL] [Abstract][Full Text] [Related]
10. Selective heterologous regulation of 5-HT1A receptor-stimulated 35S GTPgammaS binding in the anterior cingulate cortex as a result of 5-HT2 receptor activation.
Valdez M; Burke TF; Hensler JG
Brain Res; 2002 Dec; 957(1):174-82. PubMed ID: 12443993
[TBL] [Abstract][Full Text] [Related]
11. Regional variability in changes in 5-HT2A receptor mRNA levels in rat brain following irreversible inactivation with EEDQ.
Raghupathi RK; Artymyshyn R; McGonigle P
Brain Res Mol Brain Res; 1996 Jul; 39(1-2):198-206. PubMed ID: 8804728
[TBL] [Abstract][Full Text] [Related]
12. In vivo EEDQ dose-dependently inactivates rat brain 5-HT receptors but not 5-HT uptake sites.
Pinto W; Battaglia G
Neuroreport; 1993 Oct; 5(1):61-4. PubMed ID: 8280861
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical effects of lithium on serotonergic receptor function: an immunocytochemical, behavioural and autoradiographic study.
Moorman JM; Leslie RA
Neuropharmacology; 1998; 37(3):357-74. PubMed ID: 9681934
[TBL] [Abstract][Full Text] [Related]
14. The effect of chronic ritanserin and clorgyline administration on 5-HT2 receptor linked inositol phospholipid hydrolysis.
Twist EC; Brammer MJ; Stephenson JD; Corn TH; Campbell IC
Biochem Pharmacol; 1990 Nov; 40(9):2111-6. PubMed ID: 2122900
[TBL] [Abstract][Full Text] [Related]
15. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
Marek GJ; Aghajanian GK
J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
Kleven MS; Assié MB; Koek W
J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338
[TBL] [Abstract][Full Text] [Related]
17. Autoradiographic analysis of 5-HT2A binding sites in the brain of Sardinian alcohol-preferring and nonpreferring rats.
Ciccocioppo R; Angeletti S; Colombo G; Gessa G; Massi M
Eur J Pharmacol; 1999 May; 373(1):13-9. PubMed ID: 10408247
[TBL] [Abstract][Full Text] [Related]
18. Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists.
López-Giménez JF; Villazón M; Brea J; Loza MI; Palacios JM; Mengod G; Vilaró MT
Mol Pharmacol; 2001 Oct; 60(4):690-9. PubMed ID: 11562430
[TBL] [Abstract][Full Text] [Related]
19. In vitro autoradiography of serotonin 5-HT(2A/2C) receptor-activated G protein: guanosine-5'-(gamma-[(35)S]thio)triphosphate binding in rat brain.
Adlersberg M; Arango V; Hsiung S; Mann JJ; Underwood MD; Liu K; Kassir SA; Ruggiero DA; Tamir H
J Neurosci Res; 2000 Sep; 61(6):674-85. PubMed ID: 10972964
[TBL] [Abstract][Full Text] [Related]
20. Agonist induced-phosphorylation of Galpha11 protein reduces coupling to 5-HT2A receptors.
Shi J; Damjanoska KJ; Singh RK; Carrasco GA; Garcia F; Grippo AJ; Landry M; Sullivan NR; Battaglia G; Muma NA
J Pharmacol Exp Ther; 2007 Oct; 323(1):248-56. PubMed ID: 17646429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
